Who Was Included in the CBD Trial for Myofascial Jaw Pain
The CBD trial recruited adults with diagnosed myofascial pain of the chewing muscles and a minimum baseline pain score. Its result should be applied to that selected clinical population rather than every person reporting pain near the jaw.
Diagnosis was part of eligibility
Participants were 18 to 70 years old, had myofascial pain of the masticatory muscles and reported pain of at least 30 on a 100-mm visual analog scale. Trained oral and maxillofacial surgery residents used the Diagnostic Criteria for Temporomandibular Disorders and were blinded to treatment assignment.
The protocol excluded current cannabis use, recent traumatic injury of the relevant muscles or joint, mandibular fracture, pregnancy or breastfeeding, and specified recent changes in additional myofascial-pain treatment. These restrictions shaped whom the study could inform.
A diagnostic boundary is not an efficacy subgroup result
The trial compared 20 mg daily CBD oil with hemp seed oil. It did not find a significant between-group pain difference. Both groups improved on jaw function without a demonstrated CBD-specific advantage.
The eligibility criteria do not establish what the treatment would do in excluded patients. Nor do they show that a different cause of jaw pain would respond better or worse; that would require evidence for that condition.
Matching a clinical claim to the evidence
Before using this paper to support a statement about “jaw pain,” identify the actual diagnosis and population in the claim. The paper offers a controlled human test in a defined myofascial condition. Its small single-center sample, specific regimen and follow-up limit broader conclusions, and it supplies no evidence about cannabinoid concentrations or impairment.
Related analysis: the CBD jaw-pain trial’s pain and function results.
Research cited
Reeve and colleagues (2026), Oral Cannabidiol in the Treatment of Myofascial Pain Disorder of the Temporomandibular Region: A Placebo-Controlled Randomized Clinical Trial. DOI: 10.1159/000551040.
